Roche announces Phase III Results for Giredestrant

ROCHE HOLDING AG RO:

• POSITIVE PHASE III RESULTS SHOW ROCHE’S GIREDESTRANT SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN ER-POSITIVE ADVANCED BREAST CANCER

• DATA TO BE PRESENTED AT MEDICAL MEETING

• EVERA STUDY MEETS CO-PRIMARY ENDPOINTS WITH GIREDRESTRANT PLUS EVEROLIMUS